Pre-Chemotherapy Levels of Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Metastatic Cancer Patients from the Hypercan Study

ConclusionsThe current analysis of prospectively collected data shows the utility of detecting circulating thrombotic biomarkers in specific cancer types. In particular, in GI metastatic cancer, the levels of D-dimer and TG before starting chemotherapy, together with having a GI cancer, could predict EDP (within 6 months) and early deaths (within 12 months). This was not the case for NSCL cancer. Currently, new tests involving other coagulation biomarkers are ongoing and will be evaluated.Project funded by AIRC "5xMILLE" n. 12237 grant from the "Italian Association for Cancer Research (AIRC)".* On behalf of the HYPERCAN investigators.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Falanga, A., Giaccherini, C., Verzeroli, C., Marchetti, M., Russo, L., Masci, G., Celio, L., Merelli, B., Sarmiento, R., Ghilardi, M., Tartari, C. J., Brevi, S., Caldara, G., Gamba, S., Malighetti, P., Spinelli, D., Santoro, A., De Braud, F., Gasparini, G Tags: 331. Pathophysiology of Thrombosis: Poster III Source Type: research